Lee HW, Yip TCF, Tse YK, et al. - Among cirrhotic patients taking antiviral therapy for chronic hepatitis B, researchers assessed the incidence and predictors of hepatic decompensation. Researchers used two prospective hepatitis B virus (HBV) cohorts from Hong Kong and South Korea for a post hoc analysis, including patients with a liver stiffness measurement ≥10 kPa and compensated liver disease at baseline. The primary outcome included incident hepatic decompensation (jaundice or cirrhotic complications) with competing risk analysis. The analysis included a total of 818 patients with a mean age of 54.9 years (519 male [63.4%]). In HBV-related cirrhosis, hepatic decompensation is not common but not eradicated in patients receiving antiviral therapy; only a third of decompensating events are secondary to HCC. The study demonstrates that the Baveno VI criteria can be effectively used in this population to distinguish individuals at risk of decompensation.